HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cerebrospinal fluid biomarkers can play a pivotal role in the diagnostic work up of primary progressive aphasia.

AbstractBACKGROUND:
Three variants of primary progressive aphasia (PPA) have been currently characterized: non fluent/agrammatic (nfv-PPA), semantic (sv-PPA), and logopenic variant (lv-PPA). lv-PPA is most commonly associated with Alzheimer's disease (AD), while nfv-PPA and sv-PPA are related to frontotemporal lobar degeneration.
OBJECTIVE:
We aimed to determine whether cerebrospinal fluid (CSF) amyloid-β42 (Aβ42), total tau protein (t-tau), and phosphorylated tau (p-tau), frequently abnormal in AD, could constitute a useful tool in the PPA diagnostic work up, in order to identify subjects with an underlying AD pathology.
METHODS:
We measured CSF biomarker levels in a group of twenty-eight patients, fourteen lv-PPA, nine nfv-PPA, and five sv-PPA.
RESULTS:
Since there were no significant differences in any of the parameters investigated between nfv-PPA and sv-PPA, the two groups were considered as one (nfv/sv-PPA). At diagnosis, lv-PPA were older than nfv/sv-PPA patients (mean values: 70.7 versus 64.6 years, p = 0.02). CSF biomarker mean concentrations were significantly different in lv-PPA versus nfv/sv-PPA patients (p = 0.000): Aβ42 350.64 versus 661.64 ng/L; tau 631.21 versus 232.71 ng/L; p-tau 101 versus 38.21 ng/L. According to the recent AD diagnostic criteria, (Cummings et al., 2013) eleven lv-PPA and only one nfv/sv-PPA showed a liquoral pattern typical for AD. Finally lv-PPA had CSF biomarker levels very similar to a sample of 72 AD patients from our Department.
CONCLUSIONS:
Our data showed that CSF biomarkers can easily and reliably detect those patients with language disorders due to an underlying AD pathology, thus offering the possibility of targeted therapeutic interventions. However, because of the small sample size, such analyses should be reproduced in larger populations of patients to confirm our data.
AuthorsRoberto Santangelo, Elisabetta Coppi, Laura Ferrari, Maria Paola Bernasconi, Patrizia Pinto, Gabriella Passerini, Giancarlo Comi, Giuseppe Magnani
JournalJournal of Alzheimer's disease : JAD (J Alzheimers Dis) Vol. 43 Issue 4 Pg. 1429-40 ( 2015) ISSN: 1875-8908 [Electronic] Netherlands
PMID25201781 (Publication Type: Journal Article)
Chemical References
  • Amyloid beta-Peptides
  • Biomarkers
  • MAPT protein, human
  • Peptide Fragments
  • amyloid beta-protein (1-42)
  • tau Proteins
Topics
  • Age Factors
  • Aged
  • Alzheimer Disease (cerebrospinal fluid)
  • Amyloid beta-Peptides (cerebrospinal fluid)
  • Aphasia, Primary Progressive (cerebrospinal fluid, diagnosis)
  • Biomarkers (cerebrospinal fluid)
  • Humans
  • Mental Status Schedule
  • Middle Aged
  • Peptide Fragments (cerebrospinal fluid)
  • Phosphorylation
  • tau Proteins (cerebrospinal fluid)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: